PDCD1 and neoplasm: Toripalimab, a humanized anti-PD-1 IgG4 monoclonal antibody, has exhibited promising anti-tumor effectiveness in melanoma, lung cancer, hepatobiliary and pancreatic tumors, and other cancer types19.